Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera.

Blood - 15 Sept 2006

Lippert Eric, Boissinot Marjorie, Kralovics Robert, Girodon François, Dobo Irène, Praloran Vincent, Boiret-Dupré Nathalie, Skoda Radek C, Hermouet Sylvie

Abstract excerpt

We determined the allelic frequency of the JAK2-V617F mutation in DNA and assessed the expression levels of the mutant and wild-type JAK2 mRNA in granulocytes from 60 patients with essential thrombocythemia (ET) and 62 patients with polycythemia vera (PV) at the time of diagnosis. Using allele-sp...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acid Substitution
Share to Granulocytes
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Point Mutation

Share to Polycythemia Vera

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins

Share to Thrombocythemia, Essential

Source

Identifiers

PMID: 16728702
DOI: 10.1182/blood-2006-01-013540

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-16728702-2026-09-02.1. Manifest publication-graph-cohort-2026-09-02.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera.PMID 16728702Read ↗

The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.Semantic proximity Read ↗

Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemiaSemantic proximity Read ↗

Comparison of clinicopathologic findings according to JAK2 V617F mutation in patients with essential thrombocythemia.Semantic proximity Read ↗

JAK-2 mutations and their relevance to myeloproliferative diseaseSemantic proximity Read ↗

The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera.Semantic proximity Read ↗

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.Semantic proximity Read ↗

V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosisSemantic proximity Read ↗

Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis.Semantic proximity Read ↗

The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia veraSemantic proximity Read ↗

Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burdenSemantic proximity Read ↗

Clinical correlates of JAK2V617F allele burden in essential thrombocythemia.Semantic proximity Read ↗

Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.